益生菌在根除幽门螺杆菌治疗中作用的探讨

The role of probiotics in the treatment of Helicobacter pylori eradication

目的探讨益生菌在根除幽门螺杆菌（Hp）治疗中的作用。方法将240例Hp感染患者随机分为4组：三联治疗组（A组）、双歧杆菌三联活菌＋三联治疗组（B组）、四联治疗组（C组）、双歧杆菌三联活菌＋四联治疗组（D组），每组60例，比较各组Hp根除率及不良反应发生率。结果B、c、D组Hp根除率均高于A组（86．0％、89．8％、93．1％与70．7％，P〈0．05），B、C、D组间Hp根除率比较差异无统计学意义（P〉0．05）；B、D组的消化系统不良反应发生率明显低于A、C组（P〈0．05），而非消化系统不良反应发生率与A、C组比较差异无统计学意义（P〉0．05）。结论益生菌在Hp根除治疗中，能提高三联方案的根除率，对四联方案的根除率无明显影响，但能减少治疗过程中药物引起的胃肠道不良反应。

Objective To investigate the role of probiotics in the treatment of Helicobacter pylori （Hp） eradication. Methods 240 cases of Hp infected patients were randomly divided into treatment group（ group A）, bifidobacterium triple viable compound triple therapy group （group B ）, the quadruple therapy group（ group C）, bifidobacterium triple viable compound quadruple therapy group（ group D）, the rates of Hp eradication and incidence of adverse reactions were compared between each groups. Results Hp eradication rates of B, C, D group were higher than that of group A （ 86.0% , 89.8% , 93. 1% vs 70.7 %, P 〈 0.05 ）, there were no significant statistic difference in eradication rate among B, C, D groups （P 〉 0.05）. The incidence of gastrointestinal adverse reactions in group B and D was lower than that in group A and C （ P 〈 0.05 ）, when campared the incidence of non-gastrointestinal adverse reactions with group B, D and group A, C, there were no significant statistic difference （ P 〉 0.05 ）. Conclusion In Hp eradication therapy, probiotics can improve the rate of triple eradication program, can not improve the rate of quadruple eradication program. Probiotics can significantly reduce the gastrointestinal adverse reaction in the treatment process.